OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes. Ocugen, Inc.

The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been ...

Australian researchers have identified an association between nocturnal hypoxia and neovascular age-related degeneration (nAMD). 1 Acting on this realization could prevent nAMD in some patients, ...

UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual outcomes in DME patients by addressing treatment ...

A research team from Great Britain identified factors, such as mental health issues, lack of diabetic eye screening awareness, and transport difficulties, that interfere with attendance at annual ...

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar ...

Panelists discuss how successful port delivery system (PDS) implantation requires careful patient selection and meticulous surgical technique to minimize complications like vitreous hemorrhage and ...

Several pharmaceutical companies have announced new appointments of executives and board members as they prepare for growth in 2025. With the start of 2025, many companies have evaluated the skills ...

4DMT announced the publication of preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform, intravitreal R100 vector, and the R100-based genetic medicine 4D-150.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas. The US Food and Drug Administration (FDA) has accepted the revised ...

The Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial convened and approved continuation of the second phase of the Phase 1/2 study. The candidate being evaluated, OCU410 ...